摘要
目的测定头孢美唑和头孢西丁对产ESBLs菌株的体外抗菌活性,并与非产ESBLs菌株的体外抗菌活性相比较。方法收集2004年1—12月华西医院各临床科室分离出的大肠埃希菌和肺炎克雷伯菌520株,采用Kirby-Bauer琼脂扩散法进行体外药敏试验并用表型确证试验检测ESBLs。结果筛选出产ESBLs菌226株,产酶菌检出率为43.5%,其中323株大肠埃希菌的ESBLs检出率为45.8%,197株肺炎克雷伯菌的ESBLs检出率为39.6%。头孢美唑对我院产ESBLs菌株体外抗菌活性优于头孢西丁。结论头霉素类抗生素可作为治疗产ESBLs菌株引起的感染的可选药物,但仍应参考药敏试验结果。我院分离的产ESBLs大肠埃希菌和肺炎克雷伯菌对头孢美唑的敏感性略优于头孢西丁。
ObjectiveTo determine the in vitro antimicrobial activity of cefmetazole and cefoxitin against extended-spectrum beta-lactamases(ESBLs) producing and non-producing strains.MethodsA total of 520 strains of K.pneumoniae and E.coli were isolated from January 2004 to December 2004.Phenotypic confirmatory test was used to detect ESBLs.Kirby-Bauer agar diffusion method was used for susceptibility testing.ResultsOverall,226 ESBLs-producing strains were detected.The positive rate of ESBLs was 43.5%,specifically 45.8% among E.coli isolates and 39.6% among K.pneumoniae.In vitro antimicrobial activity of cefmetazole against ESBLs producing strains was higher than that of cefoxitin in West China Hospital.ConclusionsCephamycins can be the alternative treatment for ESBLs producing strains.The in vitro antimicrobial activity of cefmetazole against ESBLs producing strains is higher than that of cefoxitin in West China Hospital.
出处
《中国感染与化疗杂志》
CAS
2006年第1期50-52,共3页
Chinese Journal of Infection and Chemotherapy
关键词
头孢美唑
头孢西丁
超广谱Β内酰胺酶
体外抗菌活性
Cefmetazole
Cefoxitin
Extended-spectrum beta-lactamases
In vitro antimicrobial activity
